P3, N=376, Active, not recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Recruiting --> Active, not recruiting

Our studies suggest EphA2 on tumor cells recruits monocytes and promotes their differentiation into TAMs that likely inhibit the activation and infiltration of cytotoxic lymphocytes, promoting tumor immune escape.

Furthermore, synthetic pathways for each series or key compounds are presented, offering a practical guide for researchers in the field. By integrating these elements, this review provides a solid foundation and rationale for the design, synthesis, and optimization of new pyrazole-based anticancer agents targeting receptor tyrosine kinases.

We identified three risk factors: (1) PIK3CA-AKT/RAS-RAF alterations, (2) age ≤50, and (3) PD-L1 ≥50%. Patients with these factors had poor PFS regardless of EGFR-TKI generation.

The ADMET predictions indicated excellent drug-like properties, particularly for the non-Pgp substrate series. The finding successfully identified compound 3k as a lead dual inhibitor of VEGFR-2 and EGFR with significant anticancer activity and selectivity.

This meta-analysis suggests that the addition of ICIs to C/A may improve survival outcomes in patients with advanced NSCLC after resistance to EGFR-TKIs, particularly in selected subpopulations such as those with high PD-L1 expression or specific EGFR mutations. However, careful monitoring for specific AEs is warranted.

These findings confirm the presence of DDIs between EGFR TKIs and rivaroxaban. Avitinib and gefitinib significantly inhibit rivaroxaban metabolism, and their co-administration may aggravate the risk of bleeding.

HF is a promising natural product for overcoming NSCLC resistance to third-generation epidermal growth factor receptors-TKIs.

The analysis of mutation profiles and survival outcomes revealed that the transformation subtype affects prognosis. Additionally, the time taken to undergo transformation is critical for patient outcomes.

P1, N=14, Terminated, Allist Pharmaceuticals, Inc. | Unknown status --> Terminated; Indications have been approved for marketing

P2, N=115, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting --> Completed | Phase classification: PN/A --> P2 | N=330 --> 115 | Trial completion date: Dec 2022 --> Jun 2024

P3, N=674, Active, not recruiting, AstraZeneca | Trial completion date: Jan 2025 --> Dec 2025